Aclaris Therapeutics, Inc. Stock price

Equities

ACRS

US00461U1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:22:53 2024-03-28 am EDT 5-day change 1st Jan Change
1.255 USD -0.40% Intraday chart for Aclaris Therapeutics, Inc. +4.90% +19.89%
Sales 2024 * 7.78M Sales 2025 * 8.72M Capitalization 89.37M
Net income 2024 * -73M Net income 2025 * -100M EV / Sales 2024 * 2.33 x
Net cash position 2024 * 71.24M Net cash position 2025 * 157M EV / Sales 2025 * -7.8 x
P/E ratio 2024 *
-1.29 x
P/E ratio 2025 *
-1.06 x
Employees 89
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.23%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Aclaris Therapeutics, Inc.

1 day+6.78%
1 week+5.88%
Current month+5.88%
1 month+5.00%
3 months+18.87%
6 months-81.08%
Current year+20.00%
More quotes
1 week
1.13
Extreme 1.13
1.29
1 month
1.11
Extreme 1.11
1.51
Current year
0.86
Extreme 0.8555
1.51
1 year
0.59
Extreme 0.5902
11.12
3 years
0.59
Extreme 0.5902
30.38
5 years
0.59
Extreme 0.5902
30.38
10 years
0.59
Extreme 0.5902
33.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 12-06-30
Director of Finance/CFO - 16-12-31
Chief Tech/Sci/R&D Officer 68 -
Members of the board TitleAgeSince
Director/Board Member 58 17-08-08
Director/Board Member 66 19-07-01
Director/Board Member 66 17-01-24
More insiders
Date Price Change Volume
24-03-28 1.26 0.00% 140 283
24-03-27 1.26 +6.78% 1,286,232
24-03-26 1.18 +1.72% 716,343
24-03-25 1.16 +0.87% 586,693
24-03-22 1.15 -4.17% 548,773

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development (R&D) engine exploring protein kinase regulation. The Company operates through two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment includes provision of laboratory services. The Company is also engaged in identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
1.26 USD
Average target price
1.8 USD
Spread / Average Target
+42.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Aclaris Therapeutics, Inc. - Nasdaq